NRAS ASO-2

NRAS ASO-2 is an experimental **NRAS-targeting antisense oligonucleotide** developed in an academic preclinical program for **NRAS-mutant melanoma**. It is a chemically modified **GapmeR/LNA antisense oligonucleotide** designed to bind **exon 4 of NRAS mRNA**, leading to **RNase H1-mediated degradation of NRAS transcripts** and downstream suppression of **MAPK signaling**. In the cited 2025 Communications Medicine study, NRAS ASO-2 reduced NRAS mRNA, inhibited proliferation of NRAS-mutant melanoma cells, and showed effects broadly similar to the more potent companion construct NRAS ASO-1, while sparing tested NRAS wild-type non-malignant cells. The agent appears to be a **research-stage sequence-specific oligonucleotide tool compound**, not a marketed or clinical-stage product, and no commercial sponsor, INN, or brand name was identified from the provided context.

Other names

NRAS-targeting antisense oligonucleotide 2NRAS antisense oligonucleotide 2